Intestinal Benign Neoplasm disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: INT253 MIFTS: 47	Intestinal Benign Neoplasm Categories: Cancer diseases, Gastrointestinal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Intestinal Benign Neoplasm

MalaCards integrated aliases for Intestinal Benign Neoplasm:

Name: Intestinal Benign Neoplasm ¹¹ ¹⁴

Intestinal Neoplasms ⁴³ ⁷¹

Neoplasm of Intestinal Tract ¹¹

Intestinal Tumors ¹¹

Intestine Growth ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:4610

MeSH ⁴³ D007414

NCIt ⁴⁹ C3141

SNOMED-CT ⁶⁸ 126769007

UMLS ⁷¹ C0021841

Sources

Summaries for Intestinal Benign Neoplasm

Disease Ontology: ¹¹ A gastrointestinal system benign neoplasm that is located in the intestine.

MalaCards based summary: Intestinal Benign Neoplasm, also known as intestinal neoplasms, is related to colonic benign neoplasm and colorectal adenoma, and has symptoms including constipation and diarrhea. An important gene associated with Intestinal Benign Neoplasm is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are Endometrial cancer and Development EGFR signaling pathway. The drugs Bisacodyl and Lutetium Lu 177 dotatate have been mentioned in the context of this disorder. Affiliated tissues include intestine, small intestine and colon, and related phenotype is neoplasm.

Sources

Related Diseases for Intestinal Benign Neoplasm

Diseases related to Intestinal Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 472)

#	Related Disease	Score	Top Affiliating Genes
1	colonic benign neoplasm	31.8	TP53 MUTYH MLH1 MIR21 MIR18A MIR15A
2	colorectal adenoma	31.5	TP53 MUTYH MLH1 MIR532 MIR31 MIR21
3	gastric cancer	31.5	TP53 MUTYH MLH1 MIR21 MIR20A MIR192
4	adenoma	31.1	TP53 MUTYH MLH1 KRAS HRAS CTNNB1
5	adenocarcinoma	31.1	TP53 MLH1 KRAS HRAS CTNNB1 APC
6	familial adenomatous polyposis	31.0	TP53 MUTYH MLH1 KRAS HRAS CTNNB1
7	small intestine adenocarcinoma	30.7	TP53 MLH1 KRAS HRAS CTNNB1
8	endometriosis	30.5	TP53 MIR20A MIR17 MIR143 MIR142
9	gastrointestinal stromal tumor	30.5	TP53 KRAS HRAS H2AC18 CTNNB1
10	neurofibromatosis	30.4	TP53 MLH1 KRAS HRAS
11	colon adenocarcinoma	30.3	TP53 MLH1 KRAS HRAS CTNNB1 APC
12	small intestine cancer	30.3	TP53 MUTYH MLH1 KRAS HRAS CTNNB1
13	desmoid tumor	30.3	TP53 MUTYH CTNNB1 APC
14	peutz-jeghers syndrome	30.2	TP53 CTNNB1 APC
15	crohn's disease	30.2	MIR31 MIR21 MIR192 MIR142 H2AC18 CCR6
16	neurofibromatosis, type i	30.2	TP53 MLH1 KRAS HRAS
17	bap1 tumor predisposition syndrome	30.1	TP53 MUTYH MLH1 APC
18	rasopathy	30.1	TP53 KRAS HRAS CTNNB1
19	gastric adenocarcinoma	30.1	TP53 MLH1 KRAS HRAS CTNNB1 APC
20	myelodysplastic syndrome	30.0	TP53 MIR17 MIR142 KRAS HRAS H2AC18
21	rectal benign neoplasm	30.0	TP53 MLH1 MIR31 MIR20A MIR17 MIR143
22	bladder cancer	29.9	TP53 MLH1 MIR31 MIR21 MIR17 MIR143
23	endometrial cancer	29.9	TP53 MUTYH MLH1 MIR21 KRAS HRAS
24	colorectal cancer	29.8	TP53 MUTYH MLH1 MIR532 MIR31 MIR21
25	body mass index quantitative trait locus 11	29.7	TP53 MIR532 MIR21 MIR20A MIR192 MIR18A
26	lynch syndrome	29.7	TP53 MUTYH MLH1 MIR532 MIR31 MIR18A
27	intestinal disease	29.6	TP53 MIR532 MIR31 MIR21 MIR20A MIR192
28	rectum cancer	29.5	TP53 MUTYH MLH1 MIR31 MIR21 MIR20A
29	hepatocellular carcinoma	29.4	TP53 MLH1 MIR532 MIR31 MIR21 MIR20A
30	large intestine adenoma	11.1
31	cecal benign neoplasm	11.1
32	large bowel leiomyoma	11.1
33	large intestine lipoma	11.1
34	cystadenocarcinoma	10.5	TP53 MIR21 KRAS
35	ampulla of vater benign neoplasm	10.5	KRAS HRAS APC
36	periampullary adenoma	10.5	MUTYH HRAS APC
37	trachea carcinoma in situ	10.5	KRAS HRAS
38	vaginal carcinosarcoma	10.5	TP53 KRAS HRAS
39	dermatopathia pigmentosa reticularis	10.5	MIR31 KRAS HRAS
40	pancreatoblastoma	10.5	KRAS HRAS CTNNB1
41	gastrointestinal adenoma	10.5	MUTYH MLH1 APC
42	cholangiocarcinoma	10.5	TP53 MIR21 KRAS CTNNB1
43	descending colon cancer	10.5	MLH1 KRAS HRAS
44	duodenal benign neoplasm	10.5	HRAS APC
45	liver angiosarcoma	10.5	TP53 KRAS HRAS
46	feingold syndrome 1	10.5	MIR20A MIR18A MIR17
47	sigmoid neoplasm	10.5	MLH1 KRAS HRAS
48	cystadenofibroma	10.5	TP53 KRAS HRAS
49	endosalpingiosis	10.5	TP53 KRAS HRAS
50	appendix adenocarcinoma	10.5	TP53 KRAS HRAS

Graphical network of the top 20 diseases related to Intestinal Benign Neoplasm:

Sources

Symptoms & Phenotypes for Intestinal Benign Neoplasm

UMLS symptoms related to Intestinal Benign Neoplasm:

constipation; diarrhea

MGI Mouse Phenotypes related to Intestinal Benign Neoplasm:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	9.28	APC CTNNB1 HRAS KRAS MIR139 MIR31

Sources

Drugs & Therapeutics for Intestinal Benign Neoplasm

Drugs for Intestinal Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 200)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Bisacodyl

Approved

Phase 4

603-50-9

2391

Lutetium Lu 177 dotatate

Approved, Investigational

Phase 4

437608-50-9

76966897

Arginine

Approved, Investigational, Nutraceutical

Phase 4

74-79-3

6322

Lysine

Approved, Nutraceutical

Phase 4

56-87-1

5962

Cathartics

Phase 4

Laxatives

Phase 4

Pharmaceutical Solutions

Phase 4

Ciprofloxacin

Approved, Investigational

Phase 3

85721-33-1, 93107-08-5

2764

Amoxicillin

Approved, Vet_approved

Phase 3

26787-78-0

33613

Orange

Approved

Phase 3

Clavulanic acid

Approved, Vet_approved

Phase 3

58001-44-8

5280980

Cathine

Approved, Experimental, Illicit, Vet_approved, Withdrawn

Phase 3

14838-15-4, 492-39-7

131954576 4786 26934

Guaifenesin

Approved, Investigational, Vet_approved

Phase 3

93-14-1

3516

Ondansetron

Approved, Withdrawn

Phase 3

99614-02-5

4595

Levofloxacin

Approved, Investigational

Phase 3

100986-85-4

149096

Ofloxacin

Approved

Phase 3

82419-36-1

4583

Simvastatin

Approved

Phase 3

79902-63-9

54454

Morphine

Approved, Investigational

Phase 3

57-27-2

5288826

Dextromethorphan

Approved

Phase 3

125-71-3

5362449 5360696

Lanreotide

Approved

Phase 3

108736-35-2

71349 6918011

Amoxicillin-Potassium Clavulanate Combination

Phase 3

beta-Lactamase Inhibitors

Phase 3

topoisomerase I inhibitors

Phase 3

Anti-Bacterial Agents

Phase 3

Anti-Infective Agents

Phase 3

Chlorpheniramine, phenylpropanolamine drug combination

Phase 3

Calcium, Dietary

Phase 3

Cytochrome P-450 Enzyme Inhibitors

Phase 3

Antipsychotic Agents

Phase 3

Anti-Anxiety Agents

Phase 3

Neurotransmitter Agents

Phase 3

Psychotropic Drugs

Phase 3

Epoetin Alfa

Phase 3

Hematinics

Phase 3

Hypolipidemic Agents

Phase 3

Anticholesteremic Agents

Phase 3

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Phase 3

Lipid Regulating Agents

Phase 3

Excitatory Amino Acid Antagonists

Phase 3

Respiratory System Agents

Phase 3

Antitussive Agents

Phase 3

Analgesics, Opioid

Phase 3

Narcotics

Phase 3

Calcium

Nutraceutical

Phase 3

7440-70-2

271

Carmustine

Approved, Investigational

Phase 2

154-93-8

2578

Cytarabine

Approved, Investigational

Phase 2

147-94-4

6253

Pembrolizumab

Approved

Phase 1, Phase 2

1374853-91-4

254741536

Melphalan

Approved

Phase 2

148-82-3

4053 460612

Etoposide

Approved

Phase 2

33419-42-0

36462

Epirubicin

Approved

Phase 2

56420-45-2

41867

Interventional clinical trials:

(show top 50) (show all 168)

#	Name	Status	NCT ID	Phase	Drugs
1	Phase 4 Study of Comparison of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection. A Prospective Randomized Controlled Trial.	Completed	NCT01887158	Phase 4	Polyethylene glycol;Bisacodyl
2	A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment	Recruiting	NCT04524442	Phase 4	arginine/lysine
3	A Multinational, Randomized, Phase III Study of FOLFIRI With/Without Bevacizumab Versus Irinotecan With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer	Unknown status	NCT03303495	Phase 3	CPT-11;5-FU Bolus;5-FU Infusion;l-LV (dl-LV)
4	A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE]	Unknown status	NCT00445497	Phase 3	amoxicillin-clavulanate potassium;ciprofloxacin
5	A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer	Completed	NCT01996306	Phase 3	CPT-11 (Irinotecan);5-FU Bolus;5-FU Infusion;l-LV (dl-LV);Capecitabine
6	Impact of [68 Ga]-DOTANOC PET-CT on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Prospective, Multicentric Study.	Completed	NCT02608203	Phase 2, Phase 3	[68Ga]-DOTANOC PET/CT
7	Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Intestinal Cancer	Completed	NCT03350490	Phase 2, Phase 3	Life information rehabilitation therapy
8	Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer	Completed	NCT00006348	Phase 3	ondansetron
9	A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors	Completed	NCT00005590	Phase 3	levofloxacin
10	A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy	Completed	NCT00003600	Phase 3
11	Prospective, Double-Blinded, Multi-Centred, Randomised Controlled Trial of Perioperative Simvastatin Use in Elective Colorectal Surgery	Completed	NCT00994903	Phase 3	Simvastatin;Placebo
12	A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients	Completed	NCT00003687	Phase 3	dextromethorphan hydrobromide;morphine sulfate
13	Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET)	Recruiting	NCT03375320	Phase 3	Cabozantinib S-malate
14	A Phase 3, Single-arm, Open-label, Multicentre Study to Assess the Efficacy and Safety of Deep Subcutaneous Injections of Lanreotide Autogel® 120 mg Administered Every 28 Days in Chinese Participants With Unresectable, Locally Advanced or Metastatic Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs)	Active, not recruiting	NCT04852679	Phase 3	Lanreotide autogel
15	Chemoprevention of Duodenal Polyps in Familial Adenomatous Polyposis	Withdrawn	NCT00026468	Phase 2, Phase 3	exisulind
16	Is Greater Downstaging and Tumour Regression Observed When Surgery is Delayed to 12 Weeks After Completion of Chemoradiotherapy vs 6 Weeks?	Unknown status	NCT01037049	Phase 2
17	Phase 2 Study of Autologous Tumor Lysate-pulsed DC-CIK Cell in Colorectal Cancer After Surgery	Unknown status	NCT02202928	Phase 2	Chemotherapy
18	A Phase II Evaluation of High Dose Chemotherapy and Autologous Stem Cell Transplantation for Intestinal T-cell Lymphomas	Unknown status	NCT00669812	Phase 2	carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
19	Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma	Unknown status	NCT00410462	Phase 2	brostallicin;doxorubicin hydrochloride
20	Phase II Trial of Etoposide Plus Cisplatin Compared With Irinotecan Plus Cisplatin for First-line Treatment of Non-primary Pancreatic Metastatic and/or Unresectable Gastrointestinal Neuroendocrine Tumor G3 Type	Unknown status	NCT03963193	Phase 2	Etoposide;Irinotecan
21	A Single Group, Open Label, Multi-center Clinical Trial to Assess the Efficacy and Safety of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3	Unknown status	NCT03457844	Phase 2	Anlotinib
22	An Open, Single Arm, Multicenter, Exploratory Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type Patients With Metastatic Colorectal Carcinoma as 1st Therapy	Completed	NCT04080843	Phase 2	Anlotinib Hydrochloride;Capecitabine;Oxaliplatin
23	Phase Ib/II Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors	Completed	NCT03043664	Phase 1, Phase 2	Lanreotide;Pembrolizumab
24	A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas	Completed	NCT00474994	Phase 2	sunitinib malate
25	A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma	Completed	NCT00433550	Phase 2	capecitabine;irinotecan hydrochloride;oxaliplatin
26	A Phase I/II Study of Clofarabine in Patients With Relapsed T-Cell and NK-Cell Lymphomas	Completed	NCT00416351	Phase 1, Phase 2	clofarabine
27	A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma	Completed	NCT00454363	Phase 2	Pazopanib Hydrochloride
28	Gem-CHOP: A Randomized Phase II Study of Gemcitabine Combined With CHOP in Untreated Aggressive Non-Hodgkin's Lymphoma	Completed	NCT00079261	Phase 2	CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;gemcitabine hydrochloride;prednisone;vincristine sulfate
29	Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer	Completed	NCT00019474	Phase 2	fluorouracil;hydroxyurea
30	Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study	Completed	NCT00004895	Phase 2	octreotide acetate
31	A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation	Completed	NCT00589563	Phase 2	cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus
32	MMT 98 Study For Metastatic Disease Rhabdomyosarcoma And Other Malignant Soft Tissue Sarcoma Of Childhood	Completed	NCT00025441	Phase 2	carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
33	Phase II Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Soft-Tissue Sarcomas	Completed	NCT00005874	Phase 2	rubitecan
34	Phase I-II Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer	Completed	NCT01016639	Phase 1, Phase 2
35	Phase II Study of Weekly Administered High-Dose Pegylated Interferon Alfa-2B (PEGIntron) in Advanced Stage Low Grade Non-Hodgkin's Lymphoma	Completed	NCT00006039	Phase 2
36	A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy	Completed	NCT00004911	Phase 1, Phase 2
37	A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy	Completed	NCT00004910	Phase 1, Phase 2
38	Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma	Completed	NCT00006357	Phase 1, Phase 2	imatinib mesylate
39	A Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma	Completed	NCT00004066	Phase 2	docetaxel;gemcitabine hydrochloride
40	Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen	Completed	NCT00005804	Phase 2	cyclophosphamide
41	Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult	Completed	NCT00003939	Phase 2	trabectedin
42	A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer	Completed	NCT01010126	Phase 2	Temsirolimus
43	Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia	Completed	NCT00006379	Phase 2	cyclophosphamide;fludarabine phosphate
44	Pilot Study of Intraperitoneal (IP) Therapy With Cisplatin or Carboplatin and Floxuridine (FUdR) as Consolidation for Ovarian and Gastrointestinal Malignancies	Completed	NCT00005049	Phase 2	carboplatin;cisplatin;floxuridine
45	NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer: a Randomized Phase II Trial	Recruiting	NCT03280407	Phase 2	Capecitabine;FOLFOX regimen (oxaliplatin/leucovorin/5FU);CAPOX (oxaliplatin/capecitabine)
46	Apatinib Versus Bevacizumab in Combination With Second-line FOLFIRI in Patients With Metastatic Colorectal Cancer That Progressed During or After First-line Bevacizumab Plus an Oxaliplatin-based Regimen: A Randomised Phase 2 Trial	Recruiting	NCT03271255	Phase 2	Apatinib Mesylate Tablets;Bevacizumab Injection
47	A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients With Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)	Recruiting	NCT03891784	Phase 2	Abemaciclib
48	Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	Recruiting	NCT04907643	Phase 2
49	A Phase Ib/II Trial of JAB-21822 in Combination With Cetuximab in Patients With Advanced Colorectal Cancer, Small Intestine Cancer and Appendiceal Cancer With KRAS G12C Mutation	Recruiting	NCT05194995	Phase 1, Phase 2	JAB-21822;Cetuximab
50	A Phase II Study of sFOLFOXIRI in Advanced Gastroesophageal Cancer (SAGE)	Recruiting	NCT05332002	Phase 2	Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)

Search NIH Clinical Center for Intestinal Benign Neoplasm

Cochrane evidence based reviews: intestinal neoplasms

Sources

Genetic Tests for Intestinal Benign Neoplasm

Sources

Anatomical Context for Intestinal Benign Neoplasm

Organs/tissues related to Intestinal Benign Neoplasm:

FMA: Intestine

MalaCards : Small Intestine, Colon, Liver, Lung, Pancreas, Monocytes, Thyroid

Sources

Publications for Intestinal Benign Neoplasm

Articles related to Intestinal Benign Neoplasm:

(show top 50) (show all 1100)

#	Title	Authors	PMID	Year
1	Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. ⁵³ ⁶²	Greiner JW...Schlom J	12460911	2002
2	Myosin Vb as a tumor suppressor gene in intestinal cancer. ⁶²	Carton-Garcia F...Arango D	36316444	2022
3	Huang Qin Decoction inhibits the initiation of experimental colitis associated carcinogenesis by controlling the PAD4 dependent NETs. ⁶²	Pan Z...Luo X	36155218	2022
4	Meat Intake, Cooking Methods, Doneness Preferences and Risk of Gastric Adenocarcinoma in the MCC-Spain Study. ⁶²	Boldo E...MCC-Spain Researchers	36432538	2022
5	Pattern of lymph node metastases in gastric cancer: a side-study of the multicenter LOGICA-trial. ⁶²	de Jongh C...LOGICA Study Group	36103060	2022
6	Polygenic early-onset colorectal cancer in pediatric patients. ⁶²	Phen C...Rojas I	35670754	2022
7	Recent findings in Akkermansia muciniphila-regulated metabolism and its role in intestinal diseases. ⁶²	Liu MJ...Jian YP	36113229	2022
8	[Shenbai Jiedu Fang inhibits AOM/DSS-induced colorectal adenoma formation and carcinogenesis in mice via miRNA-22-mediated regulation of the PTEN/PI3K/AKT signaling pathway]. ⁶²	Liu J...Li L	36329578	2022
9	Potential Application of Small Interfering RNA in Gastro-Intestinal Tumors. ⁶²	Losurdo P...Grassi G	36297407	2022
10	TROP2 Represents a Negative Prognostic Factor in Colorectal Adenocarcinoma and Its Expression Is Associated with Features of Epithelial-Mesenchymal Transition and Invasiveness. ⁶²	Svec J...Korinek V	36077674	2022
11	Life-threatening gastrointestinal bleeding caused by jejunal heterotopic gastric mucosa in an adult dog: a rare case report. ⁶²	Merca R...Richter B	35974373	2022
12	Blocking DCIR mitigates colitis and prevents colorectal tumors by enhancing the GM-CSF-STAT5 pathway. ⁶²	Sun H...Iwakura Y	35926458	2022
13	Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia. ⁶²	Vasquez EG...Leedham SJ	35931031	2022
14	Multifocal organoids reveal clonal associations between synchronous intestinal tumors with pervasive heterogeneous drug responses. ⁶²	Jeong N...Ku JL	35853873	2022
15	Celiac disease and the surgeon. ⁶²	Thompson JS...Mannon P	35221098	2022
16	The role of short-chain fatty acids in Clostridioides difficile infection: A review. ⁶²	Ouyang ZR...Zhao JH	35545183	2022
17	Smad4 and p53 synergize in suppressing autochthonous intestinal cancer. ⁶²	Park JW...Kim HK	35274815	2022
18	MicroRNA Profile of Human Small Intestinal Tumors Compared to Colorectal Tumors. ⁶²	Nakagawa Y...Hirooka Y	35566730	2022
19	Occult colon cancer with sepsis as the primary manifestation identified by bone marrow puncture: A case report. ⁶²	Wang HJ...Zhou CJ	35434087	2022
20	Imaging PPG for In Vivo Human Tissue Perfusion Assessment during Surgery. ⁶²	Lai M...Hendriks BHW	35448221	2022
21	Tumor Necrosis Factor-α-Induced Protein 8-Like 2 Fosters Tumor-Associated Microbiota to Promote the Development of Colorectal Cancer. ⁶²	Lou Y...Wang H	35101901	2022
22	Mapping of novel loci involved in lung and colon tumor susceptibility by the use of genetically selected mouse strains. ⁶²	Borrego A...Ibanez OM	34966170	2022
23	The effects of aerobic exercise on the intestinal tumors and flora of the ApcMin/+ mouse. ⁶²	Ren J...Li B	34436759	2022
24	Multi-ancestral origin of intestinal tumors: Impact on growth, progression, and drug efficacy. ⁶²	Leystra AA...Halberg RB	34245130	2022
25	Surgery for Cronkhite-Canada syndrome complicated with intussusception: A case report and review of literature. ⁶²	Dong J...Chen YW	35317544	2022
26	Pre-Administration of Berberine Exerts Chemopreventive Effects in AOM/DSS-Induced Colitis-Associated Carcinogenesis Mice via Modulating Inflammation and Intestinal Microbiota. ⁶²	Deng J...Zou F	35215376	2022
27	Safety of sebelipase alfa for the treatment of lysosomal acid lipase deficiency. ⁶²	Ezgu F	34664536	2022
28	Qingchang Wenzhong Decoction Prevents the Occurrence of Intestinal Tumors by Regulating Intestinal Microbiota and Gasdermin E. ⁶²	Ren L...Cao P	35910578	2022
29	Oral administration of TRAIL-inducing small molecule ONC201/TIC10 prevents intestinal polyposis in the Apcmin/+ mouse model. ⁶²	Madka V...Rao CV	35693092	2022
30	Survival effects of primary and metastatic surgical treatment in metastatic small intestinal tumors: A propensity score-matching study. ⁶²	Zhou Z...Gungor C	35749551	2022
31	Research progress in the role and mechanism of LPCAT3 in metabolic related diseases and cancer. ⁶²	Shao G...Xu H	35711841	2022
32	Akkermansia muciniphila administration exacerbated the development of colitis-associated colorectal cancer in mice. ⁶²	Wang F...Liu Z	34976176	2022
33	GPR43 Suppresses Intestinal Tumor Growth by Modification of the Mammalian Target of Rapamycin Complex 1 Activity in ApcMin/+ Mice. ⁶²	Kong L...Kodama Y	34818236	2022
34	Intravenous Delivery of RNA Encoding Anti-PD-1 Human Monoclonal Antibody for Treating Intestinal Cancer. ⁶²	Wu L...Shang A	35069904	2022
35	Involvement of parathyroid hormone-related peptide in the aggressive phenotype of colorectal cancer cells. ⁶²	Novoa Diaz MB...Gentili C	34887626	2021
36	PKCλ/ι inhibition activates an ULK2-mediated interferon response to repress tumorigenesis. ⁶²	Linares JF...Moscat J	34560002	2021
37	Long noncoding RNAs in intestinal homeostasis, regeneration, and cancer. ⁶²	Yadav VK...Gupta J	33899236	2021
38	Bridging the Species Gap: Morphological and Molecular Comparison of Feline and Human Intestinal Carcinomas. ⁶²	Groll T...Steiger K	34885050	2021
39	Brg1 is required to maintain colorectal cancer stem cells. ⁶²	Yoshikawa T...Seno H	34415580	2021
40	Conditional CRISPR-Cas Genome Editing in Drosophila to Generate Intestinal Tumors. ⁶²	Bahuguna S...Boutros M	34831379	2021
41	Primary Effusion Lymphoma: Small Bowel Recurrence After Stem Cell Transplant. ⁶²	Mushtaq S...Sokol L	34820467	2021
42	WNT2 activation through proximal germline deletion predisposes to small intestinal neuroendocrine tumors and intestinal adenocarcinomas. ⁶²	Aavikko M...Aaltonen LA	34274970	2021
43	Endometriosis-associated intestinal tumors: a new challenge in clinical practice. ⁶²	Merayo Alvarez M...Florez Garcia LJ	34423648	2021
44	Litopenaeus vannamei BMAL1 Is a Critical Mediator Regulating the Expression of Glucose Transporters and Can Be Suppressed by Constant Darkness. ⁶²	Jiao L...Zhou Q	34679914	2021
45	Tumors Induce Death in Nearby Cells to Gain Competitive Advantage. ⁶²		34244214	2021
46	Anal Atresia in a Patient Who Had Undergone Hartmann Procedure. ⁶²	Sawada H...Takahashi T	34508065	2021
47	Association between intestinal neoplasms and celiac disease: A review. ⁶²	Wang M...Gao F	34616509	2021
48	Gastrointestinal Stromal Tumor Associated with Neurofibromatosis Type 1 Simulating a Neurofibrosarcoma in a Black African Adult Patient. ⁶²	Koffi GM...Soro KG	34720831	2021
49	Microenvironmental innate immune signaling and cell mechanical responses promote tumor growth. ⁶²	Zhou J...Boutros M	34197724	2021
50	The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability. ⁶²	Pan Q...Qin J	33932349	2021

Sources

Genes for Intestinal Benign Neoplasm

Genes related to Intestinal Benign Neoplasm (0 elite genes):

(show top 50) (show all 56)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	APC	APC Regulator Of WNT Signaling Pathway	Protein Coding	13.92	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12460911 17047044
2	MIR18A	MicroRNA 18a	RNA Gene	10.16	DISEASES inferred ¹⁴ ¹⁴
3	MIR17	MicroRNA 17	RNA Gene	9.47	DISEASES inferred ¹⁴ ¹⁴
4	MIR21	MicroRNA 21	RNA Gene	9.44	DISEASES inferred ¹⁴ ¹⁴
5	MIR143	MicroRNA 143	RNA Gene	9.31	DISEASES inferred ¹⁴ ¹⁴
6	MIR31	MicroRNA 31	RNA Gene	8.66	DISEASES inferred ¹⁴ ¹⁴
7	MIR532	MicroRNA 532	RNA Gene	8.6	DISEASES inferred ¹⁴ ¹⁴
8	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	8.54	DISEASES inferred ¹⁴ ¹⁴
9	MIR20A	MicroRNA 20a	RNA Gene	8.18	DISEASES inferred ¹⁴ ¹⁴
10	CTNNB1	Catenin Beta 1	Protein Coding	8.1	DISEASES inferred ¹⁴
11	MIR139	MicroRNA 139	RNA Gene	7.98	DISEASES inferred ¹⁴ ¹⁴
12	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	7.98	DISEASES inferred ¹⁴
13	MIR15A	MicroRNA 15a	RNA Gene	7.97	DISEASES inferred ¹⁴ ¹⁴
14	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	7.9	DISEASES inferred ¹⁴
15	H2AC18	H2A Clustered Histone 18	Protein Coding	7.82	DISEASES inferred ¹⁴ ¹⁴
16	MIR192	MicroRNA 192	RNA Gene	7.72	DISEASES inferred ¹⁴ ¹⁴
17	TP53	Tumor Protein P53	Protein Coding	7.7	DISEASES inferred ¹⁴
18	MIR142	MicroRNA 142	RNA Gene	7.68	DISEASES inferred ¹⁴ ¹⁴
19	MUTYH	MutY DNA Glycosylase	Protein Coding	7.68	DISEASES inferred ¹⁴
20	MLH1	MutL Homolog 1	Protein Coding	7.51	DISEASES inferred ¹⁴
21	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	7.45	DISEASES inferred ¹⁴
22	MIR193A	MicroRNA 193a	RNA Gene	7.44	DISEASES inferred ¹⁴ ¹⁴
23	MIR200A	MicroRNA 200a	RNA Gene	7.36	DISEASES inferred ¹⁴ ¹⁴
24	MIR199A1	MicroRNA 199a-1	RNA Gene	7.32	DISEASES inferred ¹⁴ ¹⁴
25	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	7.29	DISEASES inferred ¹⁴
26	LGR5	Leucine Rich Repeat Containing G Protein-Coupled Receptor 5	Protein Coding	7.23	DISEASES inferred ¹⁴
27	MSH2	MutS Homolog 2	Protein Coding	7.17	DISEASES inferred ¹⁴
28	MSH6	MutS Homolog 6	Protein Coding	7.14	DISEASES inferred ¹⁴
29	MIR196A1	MicroRNA 196a-1	RNA Gene	7.1	DISEASES inferred ¹⁴ ¹⁴
30	CDX2	Caudal Type Homeobox 2	Protein Coding	7.08	DISEASES inferred ¹⁴
31	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	7.06	DISEASES inferred ¹⁴
32	PMS2	PMS1 Homolog 2, Mismatch Repair System Component	Protein Coding	6.97	DISEASES inferred ¹⁴
33	CCND1	Cyclin D1	Protein Coding	6.96	DISEASES inferred ¹⁴
34	CDH1	Cadherin 1	Protein Coding	6.94	DISEASES inferred ¹⁴
35	MIR1229	MicroRNA 1229	RNA Gene	6.88	DISEASES inferred ¹⁴ ¹⁴
36	SMAD4	SMAD Family Member 4	Protein Coding	6.86	DISEASES inferred ¹⁴
37	EGFR	Epidermal Growth Factor Receptor	Protein Coding	6.84	DISEASES inferred ¹⁴
38	SERPINA3	Serpin Family A Member 3	Protein Coding	6.75	DISEASES inferred ¹⁴ ¹⁴
39	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	6.71	DISEASES inferred ¹⁴
40	IL6	Interleukin 6	Protein Coding	6.71	DISEASES inferred ¹⁴
41	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	6.7	DISEASES inferred ¹⁴
42	ERCC6	ERCC Excision Repair 6, Chromatin Remodeling Factor	Protein Coding	6.65	DISEASES inferred ¹⁴ ¹⁴
43	AXIN2	Axin 2	Protein Coding	6.56	DISEASES inferred ¹⁴
44	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	6.53	DISEASES inferred ¹⁴
45	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	6.52	DISEASES inferred ¹⁴
46	HNF4A	Hepatocyte Nuclear Factor 4 Alpha	Protein Coding	6.52	DISEASES inferred ¹⁴
47	RSPO1	R-Spondin 1	Protein Coding	6.5	DISEASES inferred ¹⁴
48	AXIN1	Axin 1	Protein Coding	6.46	DISEASES inferred ¹⁴
49	POLD1	DNA Polymerase Delta 1, Catalytic Subunit	Protein Coding	6.43	DISEASES inferred ¹⁴
50	PTEN	Phosphatase And Tensin Homolog	Protein Coding	6.43	DISEASES inferred ¹⁴

Sources

Variations for Intestinal Benign Neoplasm

Sources

Expression for Intestinal Benign Neoplasm

Search GEO for disease gene expression data for Intestinal Benign Neoplasm.

Sources

Pathways for Intestinal Benign Neoplasm

Pathways related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 18)

#	Super pathways	Score	Top Affiliating Genes
1	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.47	TP53 MLH1 KRAS HRAS CTNNB1 APC
2	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.31	TP53 KRAS HRAS CTNNB1
3	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.28	TP53 KRAS HRAS CTNNB1
4	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.23	APC CTNNB1 HRAS KRAS TP53
5	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	11.98	TP53 KRAS HRAS CTNNB1
6	Colorectal Cancer Metastasis ⁶⁴	11.87	TP53 MLH1 KRAS CTNNB1 APC
7	G12-G13 in Cellular Signaling ⁶⁴	11.82	KRAS HRAS CTNNB1 APC
8	Thyroid hormones production and peripheral downstream signaling effects ⁷⁴	11.65	TP53 HRAS CTNNB1
9	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.62	TP53 KRAS HRAS
10	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	11.61	MIR20A MIR17 MIR143
11	DNA damage response (only ATM dependent) ⁷⁴	11.56	TP53 KRAS HRAS CTNNB1 APC
12	Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ⁶¹	11.54	HRAS CTNNB1 APC
13	Head and neck squamous cell carcinoma ⁷⁴	11.49	TP53 KRAS HRAS CTNNB1
14	Bladder cancer ⁷⁴	11.23	TP53 KRAS HRAS
15	miRNAs involved in DNA damage response ⁷⁴	10.99	TP53 MIR21 MIR20A MIR18A MIR17 MIR15A
16	Extracellular vesicle-mediated signaling in recipient cells ⁷⁴	10.7	KRAS HRAS CTNNB1 APC
17	TNF-alpha signaling pathway ⁷⁴ Show member pathways RAS GTPase cycle mutants ⁶⁶ Signaling by RAS GAP mutants ⁶⁶ Signaling by RAS GTPase mutants ⁶⁶	10.66	KRAS HRAS
18	MicroRNA network associated with chronic lymphocytic leukemia ⁷⁴	10.27	TP53 MIR15A

Sources

GO Terms for Intestinal Benign Neoplasm

Cellular components related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.9	MIR532 MIR31 MIR21 MIR20A MIR192 MIR18A
2	RISC complex	GO:0016442	9.6	MIR31 MIR21 MIR20A MIR192 MIR18A MIR17
3	extracellular vesicle	GO:1903561	9.35	MIR21 MIR20A MIR192 MIR17 MIR15A

Biological processes related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 20)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	10.24	TP53 MIR21 MIR17 KRAS HRAS CTNNB1
2	negative regulation of cell population proliferation	GO:0008285	10.22	TP53 MIR21 MIR15A HRAS CTNNB1 APC
3	positive regulation of apoptotic process	GO:0043065	10.19	TP53 MIR21 MIR15A CTNNB1 APC
4	negative regulation of gene expression	GO:0010629	9.97	TP53 MIR21 MIR20A MIR17 HRAS CTNNB1
5	negative regulation of angiogenesis	GO:0016525	9.91	MIR21 MIR15A MIR143 CTNNB1
6	cellular response to gamma radiation	GO:0071480	9.89	TP53 MIR21 HRAS
7	negative regulation of transforming growth factor beta receptor signaling pathway	GO:0030512	9.88	MIR17 MIR18A MIR20A TP53
8	negative regulation of inflammatory response	GO:0050728	9.85	MIR142 MIR15A MIR20A MIR31
9	positive regulation of vascular associated smooth muscle cell proliferation	GO:1904707	9.75	MIR21 MIR20A MIR17
10	negative regulation of sprouting angiogenesis	GO:1903671	9.61	MIR20A MIR18A MIR17
11	miRNA-mediated gene silencing	GO:0035195	9.6	MIR532 MIR31 MIR21 MIR20A MIR192 MIR18A
12	positive regulation of vascular associated smooth muscle cell migration	GO:1904754	9.58	MIR21 MIR20A MIR143
13	positive regulation of cardiac muscle hypertrophy in response to stress	GO:1903244	9.57	MIR20A MIR17
14	negative regulation of vascular associated smooth muscle cell apoptotic process	GO:1905460	9.56	MIR21 MIR17
15	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.55	MIR15A MIR17 MIR20A MIR21 MIR31
16	positive regulation of metalloendopeptidase activity	GO:1904685	9.54	MIR17 MIR21
17	negative regulation of vascular endothelial growth factor production	GO:1904046	9.5	MIR20A MIR17 MIR15A
18	negative regulation of interleukin-21 production	GO:0032705	9.46	MIR21 MIR192
19	negative regulation of amyloid precursor protein biosynthetic process	GO:0042985	9.43	MIR31 MIR20A MIR17
20	positive regulation of pulmonary blood vessel remodeling	GO:1905111	9.13	MIR20A MIR17 MIR143

Molecular functions related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.7	TP53 MIR31 MIR21 MIR20A MIR192 MIR17
2	mRNA base-pairing translational repressor activity	GO:1903231	9.32	MIR31 MIR21 MIR20A MIR192 MIR18A MIR17